ERIC JAGGERS: Open Payments
NPI 1902954357 · JEFFERSONVILLE, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$27,815 in 128 payments from 13 companies in 2025. Trend: 2023 $32,698 · 2024 $30,274 · 2025 $27,815
Speaker / faculty: $24,969Food & beverage: $1,967Consulting: $460Travel & lodging: $419
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 26 | $17,603 |
| Otsuka America Pharmaceutical, Inc. | 21 | $8,994 |
| Alkermes, Inc. | 34 | $377 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $199 |
| E.R. Squibb & Sons, L.L.C. | 9 | $166 |
| Neurocrine BioSciences, Inc. | 7 | $138 |
| Vanda Pharmaceuticals Inc. | 4 | $77 |
| Janssen Pharmaceuticals, Inc | 3 | $69 |
| ABBVIE INC. | 3 | $56 |
| Noven Therapeutics, LLC | 3 | $49 |
Products named: AUSTEDO XR, ABILIFY MAINTENA, UZEDY, ARISTADA, CAPLYTA, COBENFY, INGREZZA, REXULTI.
Industry payments across IN — which companies pay providers there.
